


## PHARMACEUTICAL 2020

## Equillium Inc. Rank 174 of 362





## PHARMACEUTICAL 2020

## Equillium Inc. Rank 174 of 362

The relative strengths and weaknesses of Equillium Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Equillium Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 260% points. The greatest weakness of Equillium Inc. is the variable Net Income, reducing the Economic Capital Ratio by 89% points.

The company's Economic Capital Ratio, given in the ranking table, is -167%, being 136% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	55,431
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	3,883
Liabilities, Non-Current	127
Other Assets	15
Other Compr. Net Income	16
Other Expenses	0
Other Liabilities	9,681
Other Net Income	1,127
Property and Equipment	93
Research and Development	17,640
Revenues	0
Selling, General and Administrative Expense	9,087

Output Variable	Value in 1000 USD
Assets	55,539
Liabilities	13,691
Expenses	26,727
Stockholders Equity	41,848
Net Income	-25,600
Comprehensive Net Income	-25,592
Economic Capital Ratio	-167%